ArticleCells2026
Kaempferol Restores Cilia Length Through Axonemal Microtubule Stabilization.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ciliary shortening disrupts cilium-dependent signaling and tissue homeostasis and contributes to diverse ciliopathies and acquired disorders. However, the underlying mechanisms and pharmacological strategies for restoring ciliary length remain poorly understood. Here, we identify Kaempferol (Kae) as a previously unrecognized small-molecule regulator of ciliary length. Transcriptomic profiling showed that Kae-responsive genes were enriched in cytoskeleton- and microtubule-related processes, including microtubule organization and motor protein activity, suggesting that cytoskeletal regulation may contribute to its effects on ciliary length. Further investigation demonstrated that Kae promoted ciliary elongation under basal conditions and restored ciliary length across mechanistically distinct defect models, including SARS-CoV-2 non-structural protein 13 (NSP13) expression, Ciliobrevin D-mediated dynein inhibition, and centrosomal protein 290 (CEP290) deficiency. Mechanistically, Kae enhanced microtubule stability, as indicated by increased acetylated α-tubulin (ACTUB) expression, greater resistance to nocodazole-induced depolymerization, and enhanced microtubule recovery. Consistent with these cellular effects, Kae promoted microtubule recovery and preserved ciliary ultrastructure in the NSP13-induced airway injury model in vivo. These findings establish Kae as a pharmacological modulator of ciliary length and highlight axonemal microtubule stabilization as a potential strategy for restoring dysfunctional cilia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.